Back to Search Start Over

Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation

Authors :
Gerratana, Lorenzo
Pierga, Jean Yves Ves J.Y.
Reuben, James
Davis, Andrew Adam
Wehbe, Firas F.H.
Dirix, Luc Y
Fehm, Tanja Natascha T.
Nolé, Franco
Gisbert-Criado, Rafael
Mavroudis, Dimitrios
Grisanti, Salvatore
García Sáenz, José Ángel J.A.
Stebbing, Justin
Caldas, Carlos
Gazzaniga, Paola
Manso, Luis
Zamarchi, Rita
Bonotto, Marta
Fernandez de Lascoiti, Angela
de Mattos-Arruda, Letícia
Ignatiadis, Michail
Sandri, Maria Teresa
Generali, Daniele
De Angelis, Carmine
Dawson, Sarah Jane
Janni, Wolfgang
Carañana, Vicente
Riethdorf, Sabine
Solomayer, Erich-Franz
Puglisi, Fabio
Giuliano, Mario
Pantel, Klaus
Bidard, François-Clément
Cristofanilli, Massimo
Gerratana, Lorenzo
Pierga, Jean Yves Ves J.Y.
Reuben, James
Davis, Andrew Adam
Wehbe, Firas F.H.
Dirix, Luc Y
Fehm, Tanja Natascha T.
Nolé, Franco
Gisbert-Criado, Rafael
Mavroudis, Dimitrios
Grisanti, Salvatore
García Sáenz, José Ángel J.A.
Stebbing, Justin
Caldas, Carlos
Gazzaniga, Paola
Manso, Luis
Zamarchi, Rita
Bonotto, Marta
Fernandez de Lascoiti, Angela
de Mattos-Arruda, Letícia
Ignatiadis, Michail
Sandri, Maria Teresa
Generali, Daniele
De Angelis, Carmine
Dawson, Sarah Jane
Janni, Wolfgang
Carañana, Vicente
Riethdorf, Sabine
Solomayer, Erich-Franz
Puglisi, Fabio
Giuliano, Mario
Pantel, Klaus
Bidard, François-Clément
Cristofanilli, Massimo
Source :
The oncologist, 27 (7
Publication Year :
2022

Abstract

Despite the strong prognostic stratification of circulating tumor cells (CTCs) enumeration in metastatic breast cancer (MBC), current clinical trials usually do not include a baseline CTCs in their design. This study aimed to generate a classifier for CTCs prognostic simulation in existing datasets for hypothesis generation in patients with MBC. A K-nearest neighbor machine learning algorithm was trained on a pooled dataset comprising 2436 individual MBC patients from the European Pooled Analysis Consortium and the MD Anderson Cancer Center to identify patients likely to have CTCs ≥ 5/7 mL blood (StageIVaggressive vs StageIVindolent). The model had a 65.1% accuracy and its prognostic impact resulted in a hazard ratio (HR) of 1.89 (Simulatedaggressive vs SimulatedindolentP < .001), similar to patients with actual CTCs enumeration (HR 2.76; P < .001). The classifier's performance was then tested on an independent retrospective database comprising 446 consecutive hormone receptor (HR)-positive HER2-negative MBC patients. The model further stratified clinical subgroups usually considered prognostically homogeneous such as patients with bone-only or liver metastases. Bone-only disease classified as Simulatedaggressive had a significantly worse overall survival (OS; P < .0001), while patients with liver metastases classified as Simulatedindolent had a significantly better prognosis (P < .0001). Consistent results were observed for patients who had undergone CTCs enumeration in the pooled population. The differential prognostic impact of endocrine- (ET) and chemotherapy (CT) was explored across the simulated subgroups. No significant differences were observed between ET and CT in the overall population, both in terms of progression-free survival (PFS) and OS. In contrast, a statistically significant difference, favoring CT over ET was observed among Simulatedaggressive patients (HR: 0.62; P = .030 and HR: 0.60; P = .037, respectively, for PFS and OS).<br />SCOPUS: ar.j<br />info:eu-repo/semantics/published

Details

Database :
OAIster
Journal :
The oncologist, 27 (7
Notes :
1 full-text file(s): application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1343006444
Document Type :
Electronic Resource